Cargando…

The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()

OBJECTIVES: To determine the prevalence of cryptococcal antigenemia in a UK HIV cohort and compare baseline characteristics of patients with and without cryptococcal antigenemia. METHODS: Stored sera were retrospectively tested for cryptococcal antigen (CRAG) among newly diagnosed HIV-infected perso...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sheel, Shin, Gee Yen, Wijewardana, Ishan, Vitharana, Sasiri Rivinda, Cormack, Ian, Pakianathan, Mark, Harrison, Thomas S., Bicanic, Tihana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540259/
https://www.ncbi.nlm.nih.gov/pubmed/23046967
http://dx.doi.org/10.1016/j.jinf.2012.09.014
_version_ 1782255208961671168
author Patel, Sheel
Shin, Gee Yen
Wijewardana, Ishan
Vitharana, Sasiri Rivinda
Cormack, Ian
Pakianathan, Mark
Harrison, Thomas S.
Bicanic, Tihana
author_facet Patel, Sheel
Shin, Gee Yen
Wijewardana, Ishan
Vitharana, Sasiri Rivinda
Cormack, Ian
Pakianathan, Mark
Harrison, Thomas S.
Bicanic, Tihana
author_sort Patel, Sheel
collection PubMed
description OBJECTIVES: To determine the prevalence of cryptococcal antigenemia in a UK HIV cohort and compare baseline characteristics of patients with and without cryptococcal antigenemia. METHODS: Stored sera were retrospectively tested for cryptococcal antigen (CRAG) among newly diagnosed HIV-infected persons with CD4 < 100 cells/μL, who presented to Croydon University and St George's Hospitals, London, between January 2004 and October 2010. We assessed risk factors for cryptococcal antigenemia and patient outcomes by extracting demographic and clinical information from medical records. RESULTS: 157 patients were identified with a median age of 47 and CD4 count of 26 cells/μL. 102 (65%) were of Black race and 91 (58%) of African origin. Eight patients (5%) had positive serum CRAG. 7/8 had cryptococcal meningitis (CM) as first presentation of HIV, and 1 had sub-clinical infection. 7/8 (88%) CRAG positives were of African origin compared to 84/149 (54%) of CRAG negatives (p = 0.14). Other baseline characteristics did not differ significantly. CONCLUSION: We found a 5% prevalence of cryptococcal antigenemia in newly diagnosed HIV patients with CD4 < 100 cells/μL in southwest London, the first such data for a UK HIV cohort. Cryptococcal antigenemia occurred almost exclusively in African-born individuals. We recommend a UK CRAG screening strategy targeting newly diagnosed African HIV-infected patients with CD4 < 100 cells/μL.
format Online
Article
Text
id pubmed-3540259
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-35402592013-01-09 The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort() Patel, Sheel Shin, Gee Yen Wijewardana, Ishan Vitharana, Sasiri Rivinda Cormack, Ian Pakianathan, Mark Harrison, Thomas S. Bicanic, Tihana J Infect Article OBJECTIVES: To determine the prevalence of cryptococcal antigenemia in a UK HIV cohort and compare baseline characteristics of patients with and without cryptococcal antigenemia. METHODS: Stored sera were retrospectively tested for cryptococcal antigen (CRAG) among newly diagnosed HIV-infected persons with CD4 < 100 cells/μL, who presented to Croydon University and St George's Hospitals, London, between January 2004 and October 2010. We assessed risk factors for cryptococcal antigenemia and patient outcomes by extracting demographic and clinical information from medical records. RESULTS: 157 patients were identified with a median age of 47 and CD4 count of 26 cells/μL. 102 (65%) were of Black race and 91 (58%) of African origin. Eight patients (5%) had positive serum CRAG. 7/8 had cryptococcal meningitis (CM) as first presentation of HIV, and 1 had sub-clinical infection. 7/8 (88%) CRAG positives were of African origin compared to 84/149 (54%) of CRAG negatives (p = 0.14). Other baseline characteristics did not differ significantly. CONCLUSION: We found a 5% prevalence of cryptococcal antigenemia in newly diagnosed HIV patients with CD4 < 100 cells/μL in southwest London, the first such data for a UK HIV cohort. Cryptococcal antigenemia occurred almost exclusively in African-born individuals. We recommend a UK CRAG screening strategy targeting newly diagnosed African HIV-infected patients with CD4 < 100 cells/μL. W.B. Saunders 2013-01 /pmc/articles/PMC3540259/ /pubmed/23046967 http://dx.doi.org/10.1016/j.jinf.2012.09.014 Text en © 2013 Elsevier Ltd. https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license
spellingShingle Article
Patel, Sheel
Shin, Gee Yen
Wijewardana, Ishan
Vitharana, Sasiri Rivinda
Cormack, Ian
Pakianathan, Mark
Harrison, Thomas S.
Bicanic, Tihana
The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title_full The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title_fullStr The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title_full_unstemmed The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title_short The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort()
title_sort prevalence of cryptococcal antigenemia in newly diagnosed hiv patients in a southwest london cohort()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540259/
https://www.ncbi.nlm.nih.gov/pubmed/23046967
http://dx.doi.org/10.1016/j.jinf.2012.09.014
work_keys_str_mv AT patelsheel theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT shingeeyen theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT wijewardanaishan theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT vitharanasasiririvinda theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT cormackian theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT pakianathanmark theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT harrisonthomass theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT bicanictihana theprevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT patelsheel prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT shingeeyen prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT wijewardanaishan prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT vitharanasasiririvinda prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT cormackian prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT pakianathanmark prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT harrisonthomass prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort
AT bicanictihana prevalenceofcryptococcalantigenemiainnewlydiagnosedhivpatientsinasouthwestlondoncohort